Targeting the DDR to treat cancer has gained considerable traction following the successful deployment of PARP inhibitors (PARPi) in the treatment of breast, ovarian, and prostate cancers that harbor mutations in BRCA1 and 2. The gene discussed is BRCA1; the disease is Familial prostate cancer.